Data analysis of PD-1 antibody in the treatment of melanoma patients.
IGFBP2
Immunotherapy
Melanoma
Pd-1/PD-L1
Journal
Data in brief
ISSN: 2352-3409
Titre abrégé: Data Brief
Pays: Netherlands
ID NLM: 101654995
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
10
03
2020
revised:
24
03
2020
accepted:
26
03
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
24
4
2020
Statut:
epublish
Résumé
Data presented in this article are supplementary materials to the research article entitled "IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma". Data for melanoma patients who did not receive anti-PD-1 treatment were obtained from Tianjin Medical University Cancer Institute & Hospital from February 1981 to May 2013. Kaplan-Meier was used for survival analysis. RNA sequencing data from 28 melanoma patients receiving anti-PD-1 therapy were download from GEO database (GSE78220). Cluster analysis of RNA expression was performed using R (package pheatmap). The difference of PD-L1 expression was analysed by the Boxplot (R ggplot2 package). Differences between each group were analyzed by Fisher exact test. Information of 13 melanoma patients who had failed prior chemotherapy and treated in the Tianjin Medical University Cancer Institute & Hospital between July 2015 and December 2018 was collected. The response was captured by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1).
Identifiants
pubmed: 32322636
doi: 10.1016/j.dib.2020.105523
pii: S2352-3409(20)30417-0
pii: 105523
pmc: PMC7168734
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105523Informations de copyright
© 2020 The Author(s). Published by Elsevier Inc.
Références
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
J Clin Oncol. 2018 Mar 20;36(9):850-858
pubmed: 29341833